ReviewWorld journal of gastroenterology2014
Cirrhotic cardiomyopathy: a cardiologist's perspective.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 78 citations in OpenAlex.
- Pharmacologic Stress Myocardial Perfusion Imaging with SPECT and PET in Liver Transplant Candidates: Physiologic Limitations, Current Evidence, and Future Directions.Current cardiology reports · 2026Review
- Cardiac safety of sofosbuvir-based direct-acting antivirals in hepatitis C patients with pre-existing heart disease.Clinics (Sao Paulo, Brazil) · 2026Article
- Demographic and regional trends of mortality in patients with cardiovascular disease and liver cirrhosis in the United States between 1999 and 2019.Atherosclerosis plus · 2025Article
- Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era.Journal of clinical medicine · 2025Review
- The Cardiohepatic Axis in Cirrhosis.JACC. Basic to translational science · 2025Review
- Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management.Heart failure reviews · 2025Review
- Cardiac Remodeling and Arrhythmic Burden in Pre-Transplant Cirrhotic Patients: Pathophysiological Mechanisms and Management Strategies.Biomedicines · 2025Review
- Update on the Complications and Management of Liver Cirrhosis.Medical sciences (Basel, Switzerland) · 2025Review
- The Cardiomyocyte in Cirrhosis: Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy.Reviews in cardiovascular medicine · 2024Review
- Ventricular volume asymmetry as a novel imaging biomarker for disease discrimination and outcome prediction.European heart journal open · 2024Article
- How non-alcoholic fatty liver disease and cirrhosis affect the heart.Hepatology international · 2023Review
- Diagnosing HFpEF and Predicting ESLD Liver Transplant Outcome Using HFA-PEFF Score.JACC. Asia · 2023Article
- Liver stiffness and liver function index in liver fibrosis patients afflicted with electrocardiographic abnormalities.Journal of family medicine and primary care · 2022Article
- Silymarin Administration Attenuates Cirrhotic-induced Cardiac Abnormality in the Rats: A Possible Role of βIranian journal of medical sciences · 2022Article
- Chronotropic incompetence in end-stage liver disease.PloS one · 2022Article
- What's New in Cirrhotic Cardiomyopathy?-Review Article.Journal of personalized medicine · 2021Review
- Autonomic regulation of imbalance-induced myocardial fibrosis and its mechanism in rats with cirrhosis.Experimental and therapeutic medicine · 2021Article
- Cirrhotic Cardiomyopathy: The Interplay Between Liver and Cardiac Muscle. How Does the Cardiovascular System React When the Liver is Diseased?Current cardiology reviews · 2021Review
- Cirrhotic Cardiomyopathy.Current gastroenterology reports · 2020Review
- Cirrhotic cardiomyopathy: the liver affects the heart.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac dysfunction is frequently observed in patients with cirrhosis, and has long been linked to the direct toxic effect of alcohol. Cirrhotic cardiomyopathy (CCM) has recently been identified as an entity regardless of the cirrhosis etiology. Increased cardiac output due to hyperdynamic circulation is a pathophysiological hallmark of the disease. The underlying mechanisms involved in pathogenesis of CCM are complex and involve various neurohumoral and cellular pathways, including the impaired β-receptor and calcium signaling, altered cardiomyocyte membrane physiology, elevated sympathetic nervous tone and increased activity of vasodilatory pathways predominantly through the actions of nitric oxide, carbon monoxide and endocannabinoids. The main clinical features of CCM include attenuated systolic contractility in response to physiologic or pharmacologic strain, diastolic dysfunction, electrical conductance abnormalities and chronotropic incompetence. Particularly the diastolic dysfunction with impaired ventricular relaxation and ventricular filling is a prominent feature of CCM. The underlying mechanism of diastolic dysfunction in cirrhosis is likely due to the increased myocardial wall stiffness caused by myocardial hypertrophy, fibrosis and subendothelial edema, subsequently resulting in high filling pressures of the left ventricle and atrium. Currently, no specific treatment exists for CCM. The liver transplantation is the only established effective therapy for patients with end-stage liver disease and associated cardiac failure. Liver transplantation has been shown to reverse systolic and diastolic dysfunction and the prolonged QT interval after transplantation. Here, we review the pathophysiological basis and clinical features of cirrhotic cardiomyopathy, and discuss currently available limited therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.